Mar. 29 at 10:09 PM
$BRTX ✅️ DD details from Scientist there and AI DD sources on ORS meeting: Big Pharma "Chatter" & negotiations Activity (March 29, 2026). ((( Confirmed Press Release on 3-30 by
$BRTX ! )))
Muscle Loss Concerns ( The GLP-1 critical Side Effects ):
BioPharma Drive to improve 1 most critical issue in 100 billion dollar industry is a Requirement needed from
$BRTX from ORS meeting .✅️
🔑 👍 Primary discussion in Big Pharma right now is the "quality of weight loss" provided by blockbuster drugs like Wegovy and Zepbound with Risk.
Experts , analysts and top scientist are strongly ((highlighting that 20%+ up to near 40% of weight lost on these GLP-1 drugs is actually muscle mass.)) Weight loss drugs greatly increases the risk of more falls and serious metabolic issues especially in seniors is scientific confirmed facts. 🔑 👍 BRTX-100 & Musculoskeletal Health: 🔑 🔑 Big Pharma's focus on "muscle preservation" and full "functional improvement" at the ORS Meeting aligns perfectly with BRTX-100, which targets chronic lumbar disc disease to restore function.🔑 🔑
ThermoStem® Platform: 👍 👍 BRTX’s second program, uses brown fat stem cells to target obesity and metabolic disorders !......Requirements of Big Pharma ✅️ places
$BRTX in the crosshairs of obesity-related M&A boom currently led by companies like Novo Nordisk,
$PFE , & Eli Lilly in 100 Billion dollar industry.✅️
Recent Indicators of Partnering Interest by Big Pharma
with FDA Alignment for
$BRTX near being granted a BLA is seen a "Green Light": 👍 👍.
BRTX's successful Type B FDA meeting in February 2026 confirmed that its manufacturing (CMC) and details of trial designs are 💰 💰 "registrational-ready".......
In biotech industry, this alignment acts as "de-risking" event that often precedes Big Pharma Letters of Intent (LOIs), as it ensures the drug has a clear path to approval.💰 💰
✅️ DD details above are ALL DD in print from several sources and ORS meeting sources in condensed form Only . TIA for timely DD accuracy in detailed posts. charles✅️
